TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Weight Reduction in Chronic Proteinuric IgA Nephropathy
Brief Summary: The study aims to explore the non-pharmacological treatment of IgA nephropathy by weight reduction. The investigators hypothesized that benefits of weight loss may reduce proteinuria.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: weight reduction; Type: EXPERIMENTAL; Interventions: Behavioral: weight reduction | Intervention Type: BEHAVIORAL; Name: weight reduction; Assigned to Arm(s): weight reduction
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: weight loss surgery; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopic sleeve gastrectomy | Arm Label: Lifestyle Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: weight management program | Intervention Type: PROCEDURE; Name: laparoscopic sleeve gastrectomy; Assigned to Arm(s): weight loss surgery | Intervention Type: BEHAVIORAL; Name: weight management program; Assigned to Arm(s): Lifestyle Intervention
D: Arm Label: IBW; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus extended release | Arm Label: ABW; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus extended release | Intervention Type: DRUG; Name: tacrolimus extended release; Assigned to Arm(s): ABW, IBW

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Micafungin Versus Placebo in the Nosocomial Sepsis in Patients Multi-colonized With Candida, Randomized Controlled Trial
Brief Summary: Invasive Candida infections are burdened with a high mortality rate and is very common in intensive care units. This study aims to evaluate the efficacy of empirical treatment with micafungin in adult patients with suspected invasive candidiasis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal Saline | Arm Label: Antifungal; Type: ACTIVE_COMPARATOR; Interventions: Drug: anidulafungin | Intervention Type: OTHER; Name: Normal Saline; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: anidulafungin; Assigned to Arm(s): Antifungal
B: Arm Label: Micafungin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Micafungin | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO | Intervention Type: DRUG; Name: Micafungin; Assigned to Arm(s): Micafungin | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): PLACEBO
C: Arm Label: Nystatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nystatin | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nystatin | Intervention Type: DRUG; Name: Nystatin; Assigned to Arm(s): Control, Nystatin
D: Arm Label: 1 prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Caspofungin | Arm Label: 2 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Intervention Type: DRUG; Name: Caspofungin; Assigned to Arm(s): 1 prophylaxis | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): 2 placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Versus Standard Dose Protein for Very Preterm Infants
Brief Summary: Although expressed breast milk is considered the optimal nutritional source for preterm infants, the macronutrient content is insufficient to enable optimal growth during neonatal intensive care. Optimal dose and optimal mode of administration (standardized or individualized) of enteral protein supplementation to very preterm infants have not been established.

This study aims to compare the effects on weight gain of different modes of enteral protein supplementation.


Options:
A: Arm Label: Study Human Milk Fortifier A; Type: ACTIVE_COMPARATOR; Interventions: Other: Human Milk Fortifier A | Arm Label: Study Human Milk Fortifier B; Type: EXPERIMENTAL; Interventions: Other: Human Milk Fortifier B | Intervention Type: OTHER; Name: Human Milk Fortifier A; Assigned to Arm(s): Study Human Milk Fortifier A | Intervention Type: OTHER; Name: Human Milk Fortifier B; Assigned to Arm(s): Study Human Milk Fortifier B
B: Arm Label: Individualized fortification of breast milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Individualized fortification of breast milk | Arm Label: Routine fortification of breast milk; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Routine fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Individualized fortification of breast milk; Assigned to Arm(s): Individualized fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Routine fortification of breast milk; Assigned to Arm(s): Routine fortification of breast milk
C: Arm Label: Intervention group; Type: OTHER; Interventions: Dietary Supplement: Addition of human milk fortifiers according to human milk analysis | Intervention Type: DIETARY_SUPPLEMENT; Name: Addition of human milk fortifiers according to human milk analysis; Assigned to Arm(s): Intervention group
D: Arm Label: High Dose Protein (Individualized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Individualized) | Arm Label: High Dose Protein (Standardized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Standardized) | Arm Label: Standard protein supplementation; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard Protein Supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Individualized); Assigned to Arm(s): High Dose Protein (Individualized) | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Standardized); Assigned to Arm(s): High Dose Protein (Standardized) | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard Protein Supplementation; Assigned to Arm(s): Standard protein supplementation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Versus Standard Dose Protein for Very Preterm Infants
Brief Summary: Although expressed breast milk is considered the optimal nutritional source for preterm infants, the macronutrient content is insufficient to enable optimal growth during neonatal intensive care. Optimal dose and optimal mode of administration (standardized or individualized) of enteral protein supplementation to very preterm infants have not been established.

This study aims to compare the effects on weight gain of different modes of enteral protein supplementation.


Options:
A: Arm Label: Human Milk Cream Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Human Milk Cream | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Human Milk Cream; Assigned to Arm(s): Human Milk Cream Group
B: Arm Label: High Dose Protein (Individualized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Individualized) | Arm Label: High Dose Protein (Standardized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Standardized) | Arm Label: Standard protein supplementation; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard Protein Supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Individualized); Assigned to Arm(s): High Dose Protein (Individualized) | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Standardized); Assigned to Arm(s): High Dose Protein (Standardized) | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard Protein Supplementation; Assigned to Arm(s): Standard protein supplementation
C: Arm Label: Individualized fortification of breast milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Individualized fortification of breast milk | Arm Label: Routine fortification of breast milk; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Routine fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Individualized fortification of breast milk; Assigned to Arm(s): Individualized fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Routine fortification of breast milk; Assigned to Arm(s): Routine fortification of breast milk
D: Arm Label: Individualized fortification of breast milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Individualized fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Individualized fortification of breast milk; Assigned to Arm(s): Individualized fortification of breast milk

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis
Brief Summary: The investigators will study the efficacy and side effect profile of LGG, a probiotic, in pediatric patients with acute gastroenteritis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: GB (Florestor) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: GRALB | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: GC (placebo) | Intervention Type: DRUG; Name: GB (Florestor); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: GRALB; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: GC (placebo); Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: Biothree; Assigned to Arm(s): N/A
C: Arm Label: LGG; Type: EXPERIMENTAL; Interventions: Drug: LGG | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: micro-crystalline cellulose | Intervention Type: DRUG; Name: LGG; Assigned to Arm(s): LGG | Intervention Type: DRUG; Name: micro-crystalline cellulose; Assigned to Arm(s): Placebo
D: Arm Label: Lacidofil; Type: EXPERIMENTAL; Interventions: Drug: Lacidofil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lacidofil; Assigned to Arm(s): Lacidofil

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and MR Imaging Assessments in Patients With Intermittent Claudication Following Injection of Bone Marrow Derived ALDH Bright Cells
Brief Summary: The purpose of this study is to find out if aldehyde dehydrogenase bright (ALDHbr) cells taken from a patient's bone marrow can be placed safely, via intramuscular injections, into their affected calf and lower thigh muscles and improve blood flow and/or peak walking time in patients experiencing pain associated with blocked blood vessels in the leg.


Options:
A: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: Bone marrow punction, Procedure: BM-MNC infusion | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Bone marrow punction, Procedure: Placebo infusion | Intervention Type: PROCEDURE; Name: Bone marrow punction; Assigned to Arm(s): BM-MNC, Placebo | Intervention Type: PROCEDURE; Name: BM-MNC infusion; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: Placebo infusion; Assigned to Arm(s): Placebo
B: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: bone marrow stem cells intraarterial; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow stem cells (BMC) | Arm Label: tissue repair cells intramuscular; Type: ACTIVE_COMPARATOR; Interventions: Biological: tissue repair cells (TRC) | Arm Label: tissue repair cells intraarterial; Type: ACTIVE_COMPARATOR; Interventions: Biological: tissue repair cells (TRC) | Arm Label: bone marrow stem cells intramuscular; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow stem cells (BMC) | Intervention Type: BIOLOGICAL; Name: tissue repair cells (TRC); Assigned to Arm(s): tissue repair cells intraarterial, tissue repair cells intramuscular | Intervention Type: BIOLOGICAL; Name: bone marrow stem cells (BMC); Assigned to Arm(s): bone marrow stem cells intraarterial, bone marrow stem cells intramuscular
C: Arm Label: ALD-301; Type: EXPERIMENTAL; Interventions: Biological: ALD-301 | Arm Label: Placebo (vehicle); Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (vehicle) | Intervention Type: BIOLOGICAL; Name: ALD-301; Assigned to Arm(s): ALD-301 | Intervention Type: BIOLOGICAL; Name: Placebo (vehicle); Assigned to Arm(s): Placebo (vehicle)
D: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: CD34-positive cells | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: CD34-positive cells | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline and 5% autologous plasma | Intervention Type: BIOLOGICAL; Name: CD34-positive cells; Assigned to Arm(s): Low Dose | Intervention Type: BIOLOGICAL; Name: CD34-positive cells; Assigned to Arm(s): High Dose | Intervention Type: BIOLOGICAL; Name: Saline and 5% autologous plasma; Assigned to Arm(s): Saline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and MR Imaging Assessments in Patients With Intermittent Claudication Following Injection of Bone Marrow Derived ALDH Bright Cells
Brief Summary: The purpose of this study is to find out if aldehyde dehydrogenase bright (ALDHbr) cells taken from a patient's bone marrow can be placed safely, via intramuscular injections, into their affected calf and lower thigh muscles and improve blood flow and/or peak walking time in patients experiencing pain associated with blocked blood vessels in the leg.


Options:
A: Arm Label: GM-CSF; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-Macrophage Stimulating Factor (GM-CSF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulocyte-Macrophage Stimulating Factor (GM-CSF); Assigned to Arm(s): GM-CSF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: autologous purified CD34+ cell; Type: EXPERIMENTAL; Interventions: Other: autologous purified CD34+ cells | Arm Label: autologous PB-MNC; Type: ACTIVE_COMPARATOR; Interventions: Other: autologous peripheral blood mononuclear cells | Intervention Type: OTHER; Name: autologous purified CD34+ cells; Assigned to Arm(s): autologous purified CD34+ cell | Intervention Type: OTHER; Name: autologous peripheral blood mononuclear cells; Assigned to Arm(s): autologous PB-MNC
C: Arm Label: ALD-301; Type: EXPERIMENTAL; Interventions: Biological: ALD-301 | Arm Label: Placebo (vehicle); Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (vehicle) | Intervention Type: BIOLOGICAL; Name: ALD-301; Assigned to Arm(s): ALD-301 | Intervention Type: BIOLOGICAL; Name: Placebo (vehicle); Assigned to Arm(s): Placebo (vehicle)
D: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: Bone marrow punction, Procedure: BM-MNC infusion | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Bone marrow punction, Procedure: Placebo infusion | Intervention Type: PROCEDURE; Name: Bone marrow punction; Assigned to Arm(s): BM-MNC, Placebo | Intervention Type: PROCEDURE; Name: BM-MNC infusion; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: Placebo infusion; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Educational Video to Improve Nursing Home Care in End-stage Dementia
Brief Summary: This is a 5-year cluster RCT of a video Advance Care Planning intervention vs. control among 360 nursing home residents with advanced dementia (N=180/arm) in 20 matched nursing homes (10 intervention/10 control). Clinical outcomes will be collected at baseline, and quarterly (up to 12-months) regarding goals of care preferences, advance care planning, and treatments received. The primary outcome is decisions not to be hospitalized at 6 months.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Risperidone, Drug: Escitalopram, Drug: Citalopram, Drug: Sertraline, Drug: Paroxetine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Paroxetine; Assigned to Arm(s): A
B: Arm Label: ACP Video Program; Type: EXPERIMENTAL; Interventions: Behavioral: ACP Video Program | Arm Label: Usual ACP procedures; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACP Video Program; Assigned to Arm(s): ACP Video Program
C: Arm Label: Risperidone-risperidone; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Risperidone-Placebo; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Placebo-Placebo; Type: OTHER; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Placebo-Placebo, Risperidone-Placebo, Risperidone-risperidone
D: Arm Label: Advance care planning intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Advance care planning intervention | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Advance care planning intervention; Assigned to Arm(s): Advance care planning intervention | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Usual care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Mobile Phone Text Messaging to Reduce Maternal and Infant Deaths in Remote Rural Areas in China
Brief Summary: We plan to integrate WHO educational material using mobile phone text messaging, target on pregnant women in remote rural areas in China. We hypothsized that text messaging can have major impact on reducing maternal and infant deaths in rural China because text messaging is accessible, acceptable, and affordable.


Options:
A: Arm Label: health education; Type: EXPERIMENTAL; Interventions: Other: health education | Arm Label: no health education; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: health education; Assigned to Arm(s): health education
B: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: promotional Exclusive breastfeeding text messages | Arm Label: control; Type: OTHER; Interventions: Other: promotional Exclusive breastfeeding text messages | Intervention Type: OTHER; Name: promotional Exclusive breastfeeding text messages; Assigned to Arm(s): control, intervention
C: Arm Label: Cell-phone assisted; Type: EXPERIMENTAL; Interventions: Device: Cell-phone | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cell-phone; Assigned to Arm(s): Cell-phone assisted
D: Arm Label: Stepwise intervention; Type: EXPERIMENTAL; Interventions: Other: Customized text message invitation ( Step 1a), Other: Customized automatic phone call invitation (Step 1b), Other: Secretary phone call (Step 2), Other: Health professional face-to-face appointment (Step 3) | Arm Label: Written Letter; Type: ACTIVE_COMPARATOR; Interventions: Other: Written Letter | Intervention Type: OTHER; Name: Customized text message invitation ( Step 1a); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Customized automatic phone call invitation (Step 1b); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Secretary phone call (Step 2); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Health professional face-to-face appointment (Step 3); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Written Letter; Assigned to Arm(s): Written Letter

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Mobile Phone Text Messaging to Reduce Maternal and Infant Deaths in Remote Rural Areas in China
Brief Summary: We plan to integrate WHO educational material using mobile phone text messaging, target on pregnant women in remote rural areas in China. We hypothsized that text messaging can have major impact on reducing maternal and infant deaths in rural China because text messaging is accessible, acceptable, and affordable.


Options:
A: Arm Label: Breastfeeding support; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding support | Arm Label: General Support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breastfeeding support | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding support; Assigned to Arm(s): Breastfeeding support, General Support
B: Arm Label: health education; Type: EXPERIMENTAL; Interventions: Other: health education | Arm Label: no health education; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: health education; Assigned to Arm(s): health education
C: Arm Label: visit with grandmother; Type: EXPERIMENTAL; Interventions: Behavioral: counseling sessions | Arm Label: visit without grandmother; Type: EXPERIMENTAL; Interventions: Behavioral: counseling sessions | Arm Label: no visit with grandmother; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: no visit without grandmother; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: counseling sessions; Assigned to Arm(s): visit with grandmother, visit without grandmother
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Mobile Phone Text Messaging to Reduce Maternal and Infant Deaths in Remote Rural Areas in China
Brief Summary: We plan to integrate WHO educational material using mobile phone text messaging, target on pregnant women in remote rural areas in China. We hypothsized that text messaging can have major impact on reducing maternal and infant deaths in rural China because text messaging is accessible, acceptable, and affordable.


Options:
A: Arm Label: Text message vaccine reminders; Type: EXPERIMENTAL; Interventions: Other: Text Message, Other: automated call | Arm Label: automated phone call from clinic; Type: ACTIVE_COMPARATOR; Interventions: Other: automated call | Intervention Type: OTHER; Name: Text Message; Assigned to Arm(s): Text message vaccine reminders | Intervention Type: OTHER; Name: automated call; Assigned to Arm(s): Text message vaccine reminders, automated phone call from clinic
B: Arm Label: The Cedar Project mHealth Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: The Cedar Project mHealth intervention | Arm Label: Comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Cedar Project mHealth intervention; Assigned to Arm(s): The Cedar Project mHealth Intervention
C: Arm Label: Fixed SMS, real-time monitoring; Type: EXPERIMENTAL; Interventions: Device: Fixed SMS, real-time monitoring | Arm Label: Triggered SMS, real-time monitoring; Type: EXPERIMENTAL; Interventions: Device: Triggered SMS, real-time monitoring | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Fixed SMS, real-time monitoring; Assigned to Arm(s): Fixed SMS, real-time monitoring | Intervention Type: DEVICE; Name: Triggered SMS, real-time monitoring; Assigned to Arm(s): Triggered SMS, real-time monitoring
D: Arm Label: health education; Type: EXPERIMENTAL; Interventions: Other: health education | Arm Label: no health education; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: health education; Assigned to Arm(s): health education

Answer: D